Table 1.
The characteristics of the included studies.
| References | Clinical trials registration | Phase | Age range | Type of vaccine | Dose of administration | Number of scheduled doses (time of inoculations) | Control | Number of observation group | Number of control group |
|---|---|---|---|---|---|---|---|---|---|
| Ali et al. (33) | NCT04649151 | Phase 2/3 | 12–17 | mRNA-1273 vaccine (mRNA vaccine) | 100 μg/dose | Prime and boost inoculation (0, 28 days) | Saline | 2,486 | 1,240 |
| Frenck et al. (34) | NCT04368728 | Phase 3 | 12–15 | BNT162b2 Covid-19 Vaccine (mRNA vaccine) | 30 μg/dose | Prime and boost inoculation (0, 21 days) | Saline | 1,131 | 1,129 |
| Walter et al. (35) | NCT04816643 | Phase 2/3 | 5–11 | BNT162b2 Covid-19 Vaccine (mRNA vaccine) | 10 μg/dose | Prime and boost inoculation (0, 21 days) | Saline | 1,518 | 750 |
| Han et al. (36) | NCT04551547 | Phase 1/2 | 3–17 (3–5; 6–11; 12–17) | CoronaVac (Inactivated vaccine) | 1.5 or 3 μg/dose | Prime and boost inoculation (0, 28 days) | Alum | 436 | 114 |
| Xia et al., (37) | ChiCTR2000032459 | Phase 1/2 | 3–17 (3–5; 6–12; 13–17) | BBIBP-COV (Inactivated vaccine) | 2 ug, 4 ug or 8 μg/dose | Three doses (0, 28, and 56 days) | Saline and aluminum hydroxide adjuvant | 756 | 252 |
| Zhu et al. (38) | NCT04566770 | Phase 2 | 6–17 | Ad5-vectored COVID-19 vaccine (Adenovirus vaccine) | 0.3 ml/dose | Prime and boost inoculation (0, 56 days) | Placebo containing the same excipients as the vaccine, without viral particles | 100 | 50 |